DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
LCB01-0371 is an investigational drug.
There have been 8 clinical trials for LCB01-0371. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Pulmonary, and [disabled in preview]. The leading clinical trial sponsors are LegoChem Biosciences, Inc and [disabled in preview].
There are two US patents protecting this investigational drug and nineteen international patents.
Recent Clinical Trials for LCB01-0371
|A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtrace||LegoChem Biosciences, Inc||Early Phase 1|
|A Clinical Study of LCB01-0371||LegoChem Biosciences, Inc||Phase 2|
|IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers||LegoChem Biosciences, Inc||Phase 1|
Top disease conditions for LCB01-0371
Top clinical trial sponsors for LCB01-0371
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|LCB01-0371||Start Trial||Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof||Legochem Biosciences, Inc. (Deajeon, KR)||Start Trial|
|LCB01-0371||Start Trial||Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-- (substituted methyl)oxazolidin-2-one derivatives||Legochem Biosciences, Inc. (Daejeon, KR)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|